Artificial Intelligence in Drug Regulatory Submissions in India

Author:

Shukla Vikesh Kumar1ORCID,Mittal Manvi Kumar1

Affiliation:

1. Amity Institute of Pharmacy, Amity University, Sector 125, Noida, 201301, Uttar Pradesh, India

Abstract

Abstract: Regulatory affairs are one of the most crucial connections between the pharmaceutical company and the other stakeholder’s or regulatory agencies such as FDA, EMA, etc. Strategies in drug approval and marketing to assure the quality, safety, and efficacy of the drug follow the guidelines and laws stated under the drug and cosmetic act 1940 and rules 1945. Their primary responsibility is to keep the company in compliance with changing guidelines, which necessitates constant monitoring of the most recent industry updates. Drug regulation is a complex process as every country has its own set of documentation that must be done while regulatory submissions. From drug development and drug approval to drug commercialisation, there is a large amount of documentation that must be completed with accuracy, which can be challenging for the professional to complete, therefore, this leads to the introduction of the concept of big data that can be incorporated which will map the regulations according to 5vs model of big data. Thus, to make it more efficient, we can work big data with artificial intelligence to ease the process using natural language processing. This concept will map all the rules and guidelines together and make a cluster of similar rules together. Now, users can use the tool to locate the data of interest in a single site in a more comprised universal language that can be accessed by any professional to complete the task in the given time schedule.

Publisher

Bentham Science Publishers Ltd.

Subject

General Medicine

Reference57 articles.

1. Laenen K.; The key role of regulatory affairs in the pharmaceutical industry: From drug development to commercialization, QbD Group Available from: 2023

2. ICH M4/The Common Technical Document (CTD): Comparison of Clinical Documents and Summaries Assessment Practices in the United States, Europe, and Japan. Available from: 2022

3. Aher R.; Aher P.; Ahire T.; Shahare H.V.; Nemade C.T.; Regulatory requirement and step for registration and approval of Indian drug products in overseas market. Int J Pharm Sci Rev Res 2021,68(2),54-62

4. Johnson T.; Joyner M.; DePourcq F.; et al. Using Research Metrics to Improve Timelines Proceedings from the 2nd Annual CTSA Clinical Research Management Workshop. Clin translat Sci 2010,3(6),305-8

5. Evangeline L.; Mounica N.V.; Reddy V.S.; Ngabhushanam M.V.; Reddy D.N.; Bonthagarala B.; Regulatory process and ethics for clinical trials in India (CDSCO). Pharma Innov 2017,6(4, Part C),165

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3